European licence:

ILUVIEN (Fluocinolone acetonide 190 micrograms intravitreal implant in applicator)
Indicated for the treatment of vision impairment associated with chronic diabetic macular edema (DME), considered insufficiently responsive to available therapies

View Summary of Product Characteristics (SmPC) and  Patient Information Leaflet (PIL)

Alimera Sciences and our distribution partners

Click on the map below to view contact details

ILUVIEN is distributed by Alimera Sciences in the following European countries:

  • bluePinUK, Ireland, Germany, Portugal and AustriaalimeraLogo

Our distribution partners in Europe are:partnerLogos


Our distribution partner in The Middle East:

MEAgate International FZ-LLCmeagate
Office 701, DSC tower, Dubai Studio City, P.O.Box 390615 Dubai, UAE
+97 1455 19266
info@meagate.com
meagate.com

For information about the distribution on ILUVIEN in countries that are not featured above, please contact us here

ILUVIEN marketing authorisation in Europe

ILUVIEN has been granted market authorisation in the following countries:
Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom

Date of preparation: November 2017. EUR-ILV-MMM-0390